Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
Abstract Background Most patients with advanced prostate cancer develop bone metastases, which often result in painful and debilitating skeletal-related events. Inhibitors of bone resorption, such as bisphosphonates and denosumab, can each reduce the incidence of skeletal-related events and delay th...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-09-01
|
| Series: | BMC Urology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12894-018-0393-9 |
| _version_ | 1818508492416221184 |
|---|---|
| author | Jean-Jacques Body Roger von Moos Daniela Niepel Bertrand Tombal |
| author_facet | Jean-Jacques Body Roger von Moos Daniela Niepel Bertrand Tombal |
| author_sort | Jean-Jacques Body |
| collection | DOAJ |
| description | Abstract Background Most patients with advanced prostate cancer develop bone metastases, which often result in painful and debilitating skeletal-related events. Inhibitors of bone resorption, such as bisphosphonates and denosumab, can each reduce the incidence of skeletal-related events and delay the progression of bone pain. However, these agents are associated with an increased risk of hypocalcaemia, which, although often mild and transient, can be serious and life-threatening. Here we provide practical advice on managing the risk of hypocalcaemia in patients with advanced prostate cancer who are receiving treatment with bone resorption inhibitors. Relevant references for this review were identified through searches of PubMed with the search terms ‘prostate cancer’, ‘bone-targeted agents’, ‘anti-resorptive agents’, ‘bisphosphonates’, ‘zoledronic acid’, ‘denosumab’, ‘hypocalcaemia’, and ‘hypocalcemia’. Additional references were suggested by the authors. Main text Among patients with advanced cancer receiving a bisphosphonate or denosumab, hypocalcaemia occurs most frequently in those with prostate cancer, although it can occur in patients with any tumour type. Consistent with its greater ability to inhibit bone resorption, denosumab has shown superiority in the prevention of skeletal-related events in patients with bone metastases from solid tumours. Consequently, denosumab is more likely to induce hypocalcaemia than the bisphosphonates. Likewise, various bisphosphonates have differing potencies for the inhibition of bone resorption, and thus the risk of hypocalcaemia varies between different bisphosphonates. Other risk factors for the development of hypocalcaemia include the presence of osteoblastic metastases, vitamin D deficiency, and renal insufficiency. Hypocalcaemia can lead to treatment interruption, but it is both preventable and manageable. Serum calcium concentrations should be measured, and any pre-existing hypocalcaemia should be corrected, before starting treatment with inhibitors of bone resorption. Once treatment has started, concomitant administration of calcium and vitamin D supplements is essential. Calcium concentrations should be monitored during treatment with bisphosphonates or denosumab, particularly in patients at high risk of hypocalcaemia. If hypocalcaemia is diagnosed, patients should receive treatment with calcium and vitamin D. Conclusion With preventative strategies and treatment, patients with prostate cancer who are at risk of, or who develop, hypocalcaemia should be able to continue to benefit from treatment with bisphosphonates or denosumab. |
| first_indexed | 2024-12-10T22:32:36Z |
| format | Article |
| id | doaj.art-bbf6ed147d3847dfb2b451f31dc58864 |
| institution | Directory Open Access Journal |
| issn | 1471-2490 |
| language | English |
| last_indexed | 2024-12-10T22:32:36Z |
| publishDate | 2018-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Urology |
| spelling | doaj.art-bbf6ed147d3847dfb2b451f31dc588642022-12-22T01:31:01ZengBMCBMC Urology1471-24902018-09-0118111110.1186/s12894-018-0393-9Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completionJean-Jacques Body0Roger von Moos1Daniela Niepel2Bertrand Tombal3Department of Medicine, CHU Brugmann, Université Libre de BruxellesKantonsspital GraubündenGlobal Medical Affairs, Amgen (Europe) GmbHInstitute of Clinical Research, Université Catholique de LouvainAbstract Background Most patients with advanced prostate cancer develop bone metastases, which often result in painful and debilitating skeletal-related events. Inhibitors of bone resorption, such as bisphosphonates and denosumab, can each reduce the incidence of skeletal-related events and delay the progression of bone pain. However, these agents are associated with an increased risk of hypocalcaemia, which, although often mild and transient, can be serious and life-threatening. Here we provide practical advice on managing the risk of hypocalcaemia in patients with advanced prostate cancer who are receiving treatment with bone resorption inhibitors. Relevant references for this review were identified through searches of PubMed with the search terms ‘prostate cancer’, ‘bone-targeted agents’, ‘anti-resorptive agents’, ‘bisphosphonates’, ‘zoledronic acid’, ‘denosumab’, ‘hypocalcaemia’, and ‘hypocalcemia’. Additional references were suggested by the authors. Main text Among patients with advanced cancer receiving a bisphosphonate or denosumab, hypocalcaemia occurs most frequently in those with prostate cancer, although it can occur in patients with any tumour type. Consistent with its greater ability to inhibit bone resorption, denosumab has shown superiority in the prevention of skeletal-related events in patients with bone metastases from solid tumours. Consequently, denosumab is more likely to induce hypocalcaemia than the bisphosphonates. Likewise, various bisphosphonates have differing potencies for the inhibition of bone resorption, and thus the risk of hypocalcaemia varies between different bisphosphonates. Other risk factors for the development of hypocalcaemia include the presence of osteoblastic metastases, vitamin D deficiency, and renal insufficiency. Hypocalcaemia can lead to treatment interruption, but it is both preventable and manageable. Serum calcium concentrations should be measured, and any pre-existing hypocalcaemia should be corrected, before starting treatment with inhibitors of bone resorption. Once treatment has started, concomitant administration of calcium and vitamin D supplements is essential. Calcium concentrations should be monitored during treatment with bisphosphonates or denosumab, particularly in patients at high risk of hypocalcaemia. If hypocalcaemia is diagnosed, patients should receive treatment with calcium and vitamin D. Conclusion With preventative strategies and treatment, patients with prostate cancer who are at risk of, or who develop, hypocalcaemia should be able to continue to benefit from treatment with bisphosphonates or denosumab.http://link.springer.com/article/10.1186/s12894-018-0393-9Bone-targeted agentsBisphosphonateDenosumabZoledronic acidProstate cancerHypocalcaemia |
| spellingShingle | Jean-Jacques Body Roger von Moos Daniela Niepel Bertrand Tombal Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion BMC Urology Bone-targeted agents Bisphosphonate Denosumab Zoledronic acid Prostate cancer Hypocalcaemia |
| title | Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion |
| title_full | Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion |
| title_fullStr | Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion |
| title_full_unstemmed | Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion |
| title_short | Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion |
| title_sort | hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab prevention supports treatment completion |
| topic | Bone-targeted agents Bisphosphonate Denosumab Zoledronic acid Prostate cancer Hypocalcaemia |
| url | http://link.springer.com/article/10.1186/s12894-018-0393-9 |
| work_keys_str_mv | AT jeanjacquesbody hypocalcaemiainpatientswithprostatecancertreatedwithabisphosphonateordenosumabpreventionsupportstreatmentcompletion AT rogervonmoos hypocalcaemiainpatientswithprostatecancertreatedwithabisphosphonateordenosumabpreventionsupportstreatmentcompletion AT danielaniepel hypocalcaemiainpatientswithprostatecancertreatedwithabisphosphonateordenosumabpreventionsupportstreatmentcompletion AT bertrandtombal hypocalcaemiainpatientswithprostatecancertreatedwithabisphosphonateordenosumabpreventionsupportstreatmentcompletion |